Plain-English translation of NCT07229261 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a supplement called MitoQ (mitoquinol mesylate) can help improve how blood vessels work in pregnant patients with preeclampsia, a serious condition that causes high blood pressure during pregnancy. Preeclampsia affects about 1 in 10 pregnancies and can be dangerous for both mother and baby. The medication works by reducing harmful oxidative stress in cells, which researchers believe is a key problem in preeclampsia.
Right now, there is no good medical treatment to prevent or treat preeclampsia—doctors can only manage it by delivering the baby early, which comes with risks. Researchers have discovered that excess oxidative stress (cellular damage from harmful molecules) in the placenta is a major cause of the blood vessel problems seen in preeclampsia, and this treatment may help reverse that damage.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either the medication or a placebo (a pill with no active ingredient) that you take once daily from the time you enroll until you deliver your baby. If you have severe preeclampsia, you will likely be admitted to the hospital as an inpatient; if you have milder preeclampsia, you may be managed as an outpatient. The study involves standard blood pressure monitoring and health checks that would be part of your regular preeclampsia care.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States